Evidence map›Paper›PMID 32942905›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2020

Toxicity evaluation of sulfamides and coumarins that efficiently inhibit human carbonic anhydrases.

Ashok Aspatwar, Emanuela Berrino, Silvia Bua, Fabrizio Carta, Clemente Capasso, Seppo Parkkila, Claudiu T Supuran

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ashok AspatwarFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Emanuela BerrinoNeurofarba Department, Sezione di Chimica Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Firenze, Italy.
Silvia BuaNeurofarba Department, Sezione di Chimica Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Firenze, Italy.
Fabrizio CartaNeurofarba Department, Sezione di Chimica Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Firenze, Italy.
Clemente CapassoInstitute of Biosciences and Bioresources, CNR, Napoli, Italy.ORCID https://orcid.org/0000-0003-3314-2411
Seppo ParkkilaFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID https://orcid.org/0000-0001-7323-8536
Claudiu T SupuranNeurofarba Department, Sezione di Chimica Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Firenze, Italy.ORCID https://orcid.org/0000-0003-4262-0323
University of Florence · ITTampere University · FIInstitute of Biosciences and Bioresources · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we report a toxicity study, conducted on zebrafish larvae, of a series of coumarin and sulfamide compounds that were previously reported as inhibitors of human (h) metalloenzymes, carbonic anhydrases (CAs, EC 4.2.1.1). Due to the high relevance of hCA inhibitors as theragnostic agents, it is of pivotal importance to address safety issues that may arise from the initial

Indexed as

AnimalsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesCoumarinsDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity RelationshipSulfonamidesZebrafishCarbonic Anhydrase InhibitorsCarbonic AnhydrasesCoumarinsSulfonamidesCarbonic anhydrasesinhibitorstoxicity screeningzebrafish

Identifiers

PMID32942905
PMCPMC7534274
OpenAlexW3087431861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.